The plasminogen activator inhibitor type 1 (PAI-1) constitutes the major inhibitor of the plasminogen activation process in the blood. It has been associated with the formation of thrombus and consequently with the development of cardiovascular diseases, both acute and chronic. Plasma PAI-1 levels are genetically regulated and they are related to various atherosclerosis-risk factors, such as hypertriglyceridaemia, diabetes and insulin resistance.
A polymorphism of the PAI-1 gene promoter region causes a deletion or insertion or of a ‘G’ (4G/5G) at the “675” position. The 4G allele only interacts with transcriptional enhancers, whereas the 5G allele interacts with both enhancers and suppressors, leading to lower transcription levels. Many studies have shown that PAI-1 levels are 25% higher in 4G/4G homozygotes compared to 5G/5G homozygotes and the subsequent increased risk of coronary artery disease as well as of preeclampsia during pregnancy.
The analysis is carreid out using ARMS-PCR for the detection of Factor PAI-1 4G/5G polymorphism.
Sample type: Peripheral blood in EDTA
Time to result: 1 week